Synergistic Bladder Cancer Treatment System

Publication ID: 24-11857612_0003_PTD

Published: October 28, 2025

Category:Synergistic Combinations

Legal Citation

pr1or.art Inc., “Synergistic Bladder Cancer Treatment System,” Published Technical Disclosure No. 24-11857612_0003_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857612_0003_PTD

This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,612.

Summary of the Inventive Concept

A comprehensive system integrating antigen presenting cells, IL-15 based superagonists, and cutting-edge technologies like blockchain, AI, and IoT to revolutionize bladder cancer treatment by enhancing immune response, monitoring patient outcomes, and predicting treatment efficacy.

Background and Problem Solved

The original patent disclosed a vaccine composition for treating bladder cancer using antigen presenting cells and IL-15 based superagonists. However, it lacked a comprehensive system for tracking patient response, predicting treatment outcomes, and optimizing the immune response. The new inventive concept addresses these limitations by synergistically combining the patented vaccine composition with advanced technologies to create a more powerful and effective treatment system.

Detailed Description of the Inventive Concept

The Synergistic Bladder Cancer Treatment System consists of a composition including antigen presenting cells isolated from a subject treated with Bacillus Calmette-Guerin (BCG) and cultured with IL-15 based superagonists. This composition is integrated with a blockchain-based tracking module for monitoring patient response to the composition, ensuring secure and transparent data management. Additionally, the system incorporates artificial intelligence (AI) to predict and optimize the immune response, and a sensor-enabled device for monitoring the patient's immune response and transmitting data to a cloud-based server for analysis. The system also includes a machine learning algorithm trained on data from patients treated with the composition, enabling the prediction of patient response to bladder cancer treatment.

Novelty and Inventive Step

The new claims introduce the innovative combination of the patented vaccine composition with blockchain, AI, IoT, and machine learning technologies, providing a novel and non-obvious solution for treating bladder cancer. The integration of these technologies enables a more effective and personalized treatment approach, overcoming the limitations of the original patent.

Alternative Embodiments and Variations

Alternative embodiments of the Synergistic Bladder Cancer Treatment System could include the use of different types of antigen presenting cells, varying IL-15 based superagonist formulations, or the integration of other advanced technologies like nanotechnology or gene editing. These variations would ensure broad conceptual coverage and adaptability to different treatment scenarios.

Potential Commercial Applications and Market

The Synergistic Bladder Cancer Treatment System has significant commercial potential in the oncology market, particularly in the treatment of bladder cancer. The system's ability to enhance immune response, monitor patient outcomes, and predict treatment efficacy could lead to improved patient survival rates, reduced healthcare costs, and increased market share for NantCell, Inc.

CPC Classifications

Section	Class	Group
A	A61	A61K39/04
A	A61	A61K35/15
A	A61	A61K39/00114
A	A61	A61K39/001119
A	A61	A61K39/39
A	A61	A61K2039/515
A	A61	A61K2039/585

Section 103 Obviousness Analysis (PHOSITA)

▼

Field of Art

Immunotherapy and medical biotechnology, specifically focused on cancer treatment using antigen presenting cells and immunomodulatory techniques. Requires advanced knowledge of immunology, cell biology, and medical device integration

Person of Ordinary Skill (PHOSITA) Profile

A researcher or medical professional with a PhD or equivalent experience in immunology, with expertise in cancer treatment, cell culture techniques, and emerging medical technologies. Familiar with immunotherapeutic approaches and technological integration in medical systems

Obviousness Rationale

A PHOSITA would recognize that integrating digital technologies like blockchain, AI, and IoT with existing immunotherapeutic compositions represents a predictable extension of known medical monitoring and personalization techniques. The core immunological composition remains substantially unchanged from the source patent, with technological monitoring systems added as an obvious enhancement to patient treatment and data management. The variations represent standard technological augmentation strategies commonly applied across medical treatment domains.

Obvious Combinations & Variations

Source Patent Element

Vaccine composition using antigen presenting cells isolated from BCG-treated subjects

PTD Variation

Adding blockchain-based tracking module for monitoring patient response

Obviousness Reasoning

Tracking patient treatment outcomes is a known and predictable application of digital technologies in medical systems, representing a routine design choice for improving data management and patient monitoring

Source Patent Element

IL-15 based superagonist complex for immune response

PTD Variation

Incorporating AI algorithms to predict and optimize immune response

Obviousness Reasoning

Predictive analytics and machine learning are standard techniques for analyzing complex biological data, providing a predictable and obvious method of enhancing treatment understanding

Source Patent Element

Antigen presenting cells isolated from BCG-treated subjects

PTD Variation

Integrating sensor-enabled devices for real-time immune response monitoring

Obviousness Reasoning

Continuous patient monitoring through sensor technologies is a well-established approach in medical treatment, representing a routine technological enhancement with predictable implementation strategies

Source Patent Element

Bladder cancer treatment composition

PTD Variation

Machine learning algorithm trained on patient treatment data

Obviousness Reasoning

Developing predictive models from clinical data is a standard practice in medical research, representing an obvious extension of existing data analysis techniques

35 U.S.C. § 103 Summary: Based on the teachings of US Patent 11857612, the claimed variations in the published technical disclosure represent obvious modifications to existing bladder cancer immunotherapeutic approaches. A person having ordinary skill in the art would find the integration of digital monitoring technologies with established immunological compositions to be a predictable and routine enhancement, thereby rendering potential claims covering such combinations unpatentable under 35 U.S.C. § 103.

Original Patent Information

Patent Number	US 11,857,612
Title	Bacillus Calmette-Guerin (BCG) and antigen presenting cells for treatment of bladder cancer
Assignee(s)	NantCell, Inc.